programs Today, This lead you, our fronts. the with will we Capricor two with all AJ. has on review clinical Thank of been a for busy asset, progress quarter progress CAP-XXXX. our
exosome an update of first I provide COVID-XX. hyperimmune our by DMD, the engineered response Then The and second involves muscular Duchenne the platform the treatment program involves or dystrophy, will technology. on caused
to Diego, clinical we updates, that our be Before I California. footprint will announce to our would expanding I like San discuss
and and that facility political exosome. continue enable to the teams. products, a This CAP-XXXX both to build selected our to will research, expansion out executive enhancements our pipeline include have us We will
to for provide continue area landscape, we felt As this Diego opportunity evaluated that we more San us would the talent expansion.
start Now, me DMD. with let
As delighted of accelerated been the talking for a endpoint is for a final efficacy known clinical secondary about the full the publication. have primary statistical the if you FDA Office data dataset I Tissue endpoint of trial study. or our clinical while, and in first of Advanced based Therapeutics, full of CAP-XXXX on which after submitted am X.X, X.X, see mid-PUL fraction. DMD HOPE-X we to time to of positive analysis the to otherwise ejection been The we our cardiac PUL the was with of there CBER division of secondary OTAT, from path have tell hit approval in full and a we for the our been for data working endpoint as the HOPE-X has
patients or of which to in FDA the Annual a Duchenne a including of new, more with PPMD PUL was discussion, massage, his that treatment, on treating relaxed, or made data meeting. data, bed, the is track are X.X In the move domains Recently, Based CAP-XXXX dystrophy. we to targeted Currently, before Muscular we in course position we clinical clinical CAP-XXXX. Phase Duchenne principal receive as study Parent progression the showed X negotiated of available order although one now trial. in should the but video muscular are showed tool. We patient the after video to in and are a patients video shared This and on was easily meeting of a We provide thinking through HOPE-X, open after HOPE-X video it the of the HOPE-X-OLE more improvement, his we OTAT had which receiving small. task. Dystrophy, plan at marked an video which eligible The database, that to publication or was XX changing proceed measure presentation an quality safety further way DVA, it of and The with on Phase relatively we function was this end-of-phase strength the most assessment website. these with his as updates our with was meeting, forward a study. extension have community. label of a enhance of is exciting its This related size the pivotal its relatively important PPMD to he Project patients conference will the the at to and X consensus for a life productive and using dataset patients called has all scientific of DMD
So, more excited the CAP-XXXX. about ever patients are than
committed are as registration. as potential towards work CAP-XXXX We as we to to them getting quickly possible
study, let Now, a patients in be scheme. me one-to-one design to the XX Phase briefly a X with will approximately HOPE-X the of trial. summarize XX randomization It
common, we interim in national the worldwide. are Dr. who DMD will we planning sites are Currently, UC McDonald of be approximately principal of analysis. experts is As U.S. is The XX of a on Craig Davis, building one in again pre-specified investigator the leading
ready and be operations is of goal securing start terms clinical we to trial. begun In as readiness, clinical have to the sites engaging our
we for We clinical have of ready CMC we plant commercial commercialization. continue manufacturing, to meeting the secure our at on previously to work plan FDA Lonza supply with have appropriate discussed terms as In with to time.
for providing they DMD. Further, a to diseases. updates forward that CAP-XXXX the the discussions value This agreement. line As extent also into target evaluate a instructive To long-term is other have CAP-XXXX secure is therapies discussions commercialization. trial, and is cell partner continue price to CAP-XXXX we in the definitive reimbursement positive for potential previously to our rare to partners we plan for payers been projected that up as with we to multiple take stated, pivotal with the have DMD. had terms gene who have in of through as Their are and we end, gearing for with we accelerated our look materialize potential have in of
is turn to me the trial INSPIRE, in which are conducting attention let with we my Now, COVID-XX. patients clinical
very know, Based severe, tried that a in CAP-XXXX in sequelae any Research combat a peer-reviewed active of effective. authorization of double-blinded to by and these or decided us you critical have has the been few, but the of a placebo-controlled emergency been we As series XXXX virus on patients conducted Cardiology, not published journal, to if therapies a cases, COVID. trial in randomized, conduct in with Basic use
are been widely a usually is treatments up variety was is of oxygen not evaluate that matter on properties known of have need the of purpose once use ventilator. outcome supplementation, to the no They does endpoints, because particular like? what hospital COVID-XX. Plus helping that are patients on We severe to the The was the was not are immunomodulatory in population, how a but positive, patients of enroll designed look series type were patient which are Now most of to trial and it CAP-XXXX’s selected a exploratory responsive which they emergency patients. utilized. this ventilator, in carefully the in with in patient XX to CAP-XXXX
data the fell selection will now virus possible best patient Enrollment we a line in resurgence the the Delta we seeing have are on at plan, the for will the with forward COVID. of with. nature time, dataset and in increased current near move enrollment that COVID in looking of to our the careful U.S., while slowed been impact have our be but sites, the CAP-XXXX seeing top cases anticipate At forward future. we this We on so we when variant, and of to severe based the
cardiosphere-derived of recently been co-published States the we of CAP-XXXX Army anti-shock paper use impact therapeutic, the from of Research. cells of as potential COVID-XX. data extracellular derived a a vesicles paper are One potential the the is in with encouraged the supported CAP-XXXX reasons COVID-XX data from Institute Surgical in has called our The in which about United from
mechanism mechanism CDC-EVs shock that severe this release. critical We on is impact or CAP-XXXX exosomes trauma, the the showing highlights similar the of seen of COVID. of is of that the and which pathophysiology that in have by exosomes that to cells action the And paper and published
the the potential of other CAP-XXXX are from clinical activation. of in and enthusiastically Taken for indications evaluate data we together, INSPIRE hyperimmune to COVID waiting
provide be expanding Now, would an that exosomes our products our to update on technology. I’d like we engineered portfolio we announced platform exosomes. of to A ago, year
cell also and deliver As active we furthermore, we membranes, realized to to to a deliver harnessed feature from the technology exosomes, by custom messages than great opportunity were to an power many for capitalize of of choice load able the learned payloads of deliver that able saw exosomes. exosomes the our would communication and We cell area rather from investigation therapeutics the exosomes device, cell across envisioned payloads this nature’s not derived CAP-XXXX, and a us We but allow knowledge of particular the any be to years. as that of happenstance. on they
We spent the exciting for the opportunity. year groundwork last have that laying
at we received recruited level, with where PhD Dr. people for working Vice Elliott. on First, her assembled starting Johns Christy Hopkins and University XX who who a a a the Dr. therapeutic scientists have decade more exosomes, have technology. have experience development in from team engineering President experience we our platform of of of recruited than has exosomes and team has Elliott approximately exosome
is Diego continuing have and at quarter, vaccine. developments novel based our of this build we to to out therapeutic stated, program, research previously advancing our And the results. clinical primarily team development continue our new in I research while As team efforts the our San This The pipeline. will exosome-based multivalent advanced yield COVID-XX vaccine facilities. second be in
concept combat boosters recent continue likely in enhance clear have allow of vaccines. protect variants, in coronavirus. to vaccines response leads That by Delta vaccines annual approaches proteins in the As contagious become the immune variant. virus therefore this the globally. vaccine spike resulted escape the to immunity. innovative is virus are It protein may viral seen to existing will mutations maybe variants need that against elicited current months, that to new These spike in to SARS-CoV-X necessary to Therefore, on to the necessary highly specifically becoming the mutations
a hypothesis available Phase toxicity. COVID-XX is and offer vaccines we are in currently trial. administered And vaccine any a as our protection that such, As for to booster clinical less our may to X vaccine be greater planning
what vaccine. you different our tell me let Now, about is
an lead in delivery delivered processing. payload First, antigen we to Exosomes nucleic acids is confer which specifically and exosome. more intracellular to delivery our advantages of are may vehicle, believe mRNA natural nature’s may
as of both antibody coronavirus. N Secondly, measured and the traditional of in mutate a is N construct we The protein. have conserved, doesn’t which is rapidly in S testing what highly multivalent it means and it fact, is
vaccines develop to confer well. a the We rapidly, may studies on for underway the RNAs, processes. response, the may to is do believe processed But of it our which IND potentially Because have a year. lasting as hypothesis that COVID-XX in stronger IND-enabling virus. to that immunity of B-cell protein to is well. memory We be continued or rapidly and quarter against T-cell the that against protection, intracellularly which spike N the important Our to by are are both protection COVID-XX. protect track delivering an mutates natural we current submit longer that multiple by are offer It mutating response have for or addition fourth an it SARS-CoV-X. this vaccine protein important vaccines more could very variants vaccines may the of mount is the difficult antibody
we exosome been that lays have the chain first basic FDA’s has pipeline groundwork molecule. opportunity platform our non-clinical work of delayed exosome-based one an through studies I the non-clinical company believe exosomes the which used vaccines the at present this an large our moving based that an exosome CMC-related loaded from data that the the for is exosome-based such timeline exosome-based approach. Furthermore, requests other other into clinic. were efficacy support indications and projections, multiple challenges of to for of with development original the is as conducting for a the pharmaceutical At studies this hope with a by worked maybe vaccine same, conducting biologic exploring beyond the with for to overall Although the from COVID. this supply to maybe knowledge an of time, power we vaccines studies vaccine continue
platform ongoing. expansion of our technology Finally, exosome is in addition,
development have We product additional are and programs. teams R&D our continuing exosome-based enable to and expand to
as quarters We expanded identify over indications are part few to actively working next multiple exosome our of the pipeline.
plan these to And some clinic. of take into the we
the are We use underway, two Proof-of-concept with data siRNA are investigating year. fourth programs both these of and in the of as expected initial of quarter therapeutic mRNA studies exosome part new for this programs.
strong a Taken finishing Capricor advancement been year we the the off together, anticipating technology. our platform of programs it are exosome indeed on multiple has engineered clinical quarter for with busy and
Board experience Capricor’s recently In and as Es leader up on our brings to added sciences of who we as team. her vaccine forward launch embark XX next addition, to growth. first-in-class products directed to senior a successfully our She over Karimah phase we Sabar life look years to we the of and guidance biotherapeutic global
year tuned Difficulty]. Cantor Lastly, the Conference of our including new Fitzgerald In corporate will please announcement leading regarding as a well medical to management Global be banking as and several conferences leader presenting we the team. various stay closing, the later this at senior [Technical scientific and and conferences, Healthcare
the on will call CFO Now, AJ turn update an our the to over I Bergman, financials. for
